R Squared’s West Pharmaceutical WST Stock Holding History

R Squared’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,417	Closed	-$665K	–	679
2025 Q4	$665K	Buy	+2,417	New	+$661K	0.31%	80
2025 Q3	–	Sell	-1,765	Closed	-$386K	–	726
2025 Q2	$386K	Buy	+1,765	New	+$377K	0.21%	154

Other funds holding WST

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

R Squared's WST Position: Q1 2026 in Review

R Squared sold out of West Pharmaceutical (WST) in Q1 2026, closing a stake of 2,417 shares — an estimated $665K sold.

R Squared first reported a position in WST in Q2 2025 and held it in 2 quarters. The position peaked at $665K in Q4 2025. 755 funds tracked by Wall St. Rank hold WST as of Q1 2026.

R Squared reported no remaining West Pharmaceutical position as of Q1 2026 after selling out during the quarter.
R Squared sold 2,417 West Pharmaceutical shares in Q1 2026, an estimated $665K.
R Squared first reported a position in West Pharmaceutical in Q2 2025 and held it in 2 quarters.
R Squared's West Pharmaceutical position peaked at $665K in Q4 2025.
755 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2026.

Based on R Squared's 13F filing for Q1 2026, filed 29 Apr 2026.